Combination of Aβ Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition
Christophe Verbeeck1, Anna Carrano1, Paramita Chakrabarty2
1Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida.
Abstract:
Anti-Aβ clinical trials are currently under way to determine whether preventing amyloid deposition will be beneficial in arresting progression of Alzheimer disease. Both clinical and preclinical studies suggest that antiamyloid strategies are only effective if started at early stages of the disease process in a primary prevention strategy. Because this approach will be difficult to deploy, strategies for secondary prevention aimed at later stages of disease are also needed. In this study, we asked whether combining innate immune activation in the brain with concurrent Aβ suppression could enhance plaque clearance and could improve pathologic outcomes in mice with moderate amyloid pathologic disorder. Starting at 5 months of age, tet-off amyloid precursor protein transgenic mice were treated with doxycycline (dox) to suppress further amyloid precursor protein/Aβ production, and at the same time mice were intracranially injected with adeno-associated virus 1 expressing murine IL-6 (AAV1-mIL-6). Three months later, mice treated with the combination of Aβ suppression and AAV1-mIL-6 showed significantly less plaque pathologic disorder than dox or AAV1-mIL-6 only groups. The combination of AAV1-mIL-6 + dox treatment lowered total plaque burden by >60% versus untreated controls. Treatment with either dox or AAV1-mIL-6 alone was less effective than the combination. Our results suggest a synergistic mechanism by which the up-regulation of mIL-6 was able to improve plaque clearance in the setting of Aβ suppression.
Insights
Combining brain immune activation with amyloid-beta suppression significantly reduced Alzheimer
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) plaque deposition.
- Current anti-Aβ strategies show promise but are most effective when initiated early.
- Secondary prevention strategies for later stages of AD are needed.
Purpose of the Study:
- To investigate the synergistic effects of combining innate immune activation with Aβ suppression in a mouse model of moderate Alzheimer's disease.
- To determine if this combined approach enhances plaque clearance and improves pathological outcomes.
Main Methods:
- Tet-off amyloid precursor protein transgenic mice were used.
- Mice received doxycycline (dox) to suppress Aβ production.
- Mice were intracranially injected with adeno-associated virus 1 expressing murine IL-6 (AAV1-mIL-6).
- Treatments were administered starting at 5 months of age for 3 months.
Main Results:
- Combination therapy (AAV1-mIL-6 + dox) significantly reduced plaque pathology compared to single treatments or controls.
- Total plaque burden was lowered by over 60% in the combination group versus untreated controls.
- A synergistic mechanism was observed, where IL-6 up-regulation enhanced Aβ plaque clearance during Aβ suppression.
Conclusions:
- Concurrent Aβ suppression and IL-6-mediated immune activation represent a promising synergistic strategy for enhancing amyloid plaque clearance.
- This combined approach may offer a viable secondary prevention strategy for Alzheimer's disease.
- Further research into immune modulation combined with Aβ reduction is warranted for AD therapeutics.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...